Skip to content
Therapy But Better – Lifestyle
Author:
Cardiol Therapeutics Inc. (NASDAQ: CRDL)
Correction: Positive Results on MAVERIC Phase 2 and Published ARCHER Study Presented by the Company CEO in Live Interview with Barchart: Cardiol Therapeutics Inc. (NASDAQ: CRDL)
April 27, 2026
$30 Billion Per Year US Heart Failure Market Presents Huge Opportunity for Promising Drugs Advancing with Positive Trial Results for Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL)
April 13, 2026
←
Previous Page
1
2